There are currently no generic versions of Tasmar (tolcapone). The earliest predictable date that a generic version could become available is December 2012, when the next patent for the drug expires. It is important to note that tolcapone is the "generic name" for Tasmar; it is not a generic version of it.
Generic Tasmar: An OverviewTasmar® (tolcapone) is a prescription medication that has been licensed as a Parkinson's disease treatment. It is always used with carbidopa-levodopa medications, such as Sinemet®, Sinemet CR, or Parcopa®. Due to the risks of serious liver problems, Tasmar is usually reserved for people for whom other treatment alternatives are unacceptable or have failed.
Tasmar is made by Legacy Pharmaceuticals (for the 100 mg tablets) or Hoffmann-La Roche, Inc. (for the 200 mg tablets) and marketed by Valeant Pharmaceuticals North America. At this time, no generic Tasmar is available in the United States.
When Will Generic Tasmar Be Available?
The first patent for Tasmar expired in January 2012. However, the drug is not yet available in generic form. Most likely, this means that at least one other, later-expiring patent is still protecting the medication from generic competition. The next Tasmar patent is set to expire in December 2012. This is the earliest predictable date that a generic version could become available.
However, other circumstances could arise to extend or shorten the exclusivity period. This could include such things as lawsuits or other patents for specific Tasmar uses. Once the patent expires, several companies likely will begin manufacturing a generic Tasmar drug.